Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Portola Pharmaceuticals (PTLA) Stock Price
Press coverage about Portola Pharmaceuticals (NASDAQ:PTLA) has been trending somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Portola Pharmaceuticals earned a news impact score of 0.18 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 47.3143228372803 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news stories that may have impacted Accern’s rankings:
- Brokerages Anticipate Portola Pharmaceuticals, Inc. (PTLA) to Announce -$1.51 EPS (americanbankingnews.com)
- Stocks to Buy: Ironwood Pharmaceuticals, Inc. (IRWD) ,Portola Pharmaceuticals, Inc. (PTLA) – Street Observer (press release) (streetobserver.com)
- Portola Pharmaceuticals, Inc. (PTLA) 25.30% off from 200- SMA … – Voice Of Analysts (analystsbuzz.com)
- Jim Cramer Advises His Viewers On Southwest Airlines And General Electric – Benzinga (benzinga.com)
- Cramer's lightning round: Portola's no one-trick pony (finance.yahoo.com)
PTLA has been the topic of several analyst reports. Credit Suisse Group reiterated a “neutral” rating and issued a $58.00 target price (up previously from $39.00) on shares of Portola Pharmaceuticals in a research note on Monday, June 26th. Morgan Stanley raised their price target on shares of Portola Pharmaceuticals from $50.00 to $70.00 and gave the company an “overweight” rating in a research report on Monday, June 26th. Cowen and Company raised their price target on shares of Portola Pharmaceuticals from $45.00 to $70.00 and gave the company an “outperform” rating in a research report on Monday, June 26th. Oppenheimer Holdings, Inc. boosted their price objective on shares of Portola Pharmaceuticals from $46.00 to $66.00 and gave the stock an “outperform” rating in a report on Monday, June 26th. Finally, William Blair restated an “outperform” rating on shares of Portola Pharmaceuticals in a report on Monday, June 26th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $63.77.
Shares of Portola Pharmaceuticals (PTLA) opened at 54.17 on Wednesday. The stock’s 50 day moving average is $56.05 and its 200-day moving average is $48.69. Portola Pharmaceuticals has a one year low of $15.68 and a one year high of $67.10. The stock’s market cap is $3.12 billion.
Portola Pharmaceuticals (NASDAQ:PTLA) last posted its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.10) by ($0.12). The business had revenue of $3.79 million during the quarter, compared to analyst estimates of $4.28 million. Portola Pharmaceuticals had a negative return on equity of 145.12% and a negative net margin of 807.93%. The firm’s revenue for the quarter was down 10.4% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.02) EPS. On average, equities analysts forecast that Portola Pharmaceuticals will post ($4.83) EPS for the current year.
In other Portola Pharmaceuticals news, EVP Tao Fu sold 5,812 shares of the company’s stock in a transaction that occurred on Tuesday, July 18th. The shares were sold at an average price of $65.00, for a total transaction of $377,780.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider John T. Curnutte sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 18th. The shares were sold at an average price of $65.00, for a total transaction of $650,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 39,162 shares of company stock valued at $2,428,780. 4.90% of the stock is currently owned by company insiders.
WARNING: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/10/04/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-portola-pharmaceuticals-ptla-stock-price.html.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Stock Ratings for Portola Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.